Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB Pharma and Oxford University have entered into a £3.6m research deal to develop drug candidates for immunology and neurology over the next three years.
Subscribe to our email newsletter
Both the parties will select between five and ten projects, decided on by a committee of UCB and Oxford University representatives, InPharm reported.
UCB’s immunology research center currently focuses on research for conditions such as rheumatoid arthritis, lupus, inflammatory bowel disease and osteoporosis.
Oxford University medicine regius professor John Bell said the partnerships between industry and academia will have an increasingly prominent role to play in the development of new drugs, therapies and medical technologies.
UCB chief executive Roch Doliveux said Oxford University’s academic research will dovetail with UCB’s work on antibodies.